Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2696 • ACR Convergence 2025
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Eric Morand¹, Josefina Cortés-Hernández², Zahir AMOURA³, Julia Weinmann-Menke⁴, Britta Maurer⁵, Edouard Forcade⁶, Stephanie Finzel⁷, Jose Alvaro-Gracia⁸, Marc Scherlinger⁹, Alberta Hoi¹⁰, Yannick Muller¹¹, Rangi Kandane-Rathnayake¹², Ozana Fischer¹³, Beata Kovacs¹³, Frédérique Chaperon¹³, David Pearson¹³, Adrienne Lefeber¹⁴, Chih-Yung Sean Lee¹⁴, Jianping Yuan¹⁴, Vassilis Bitsikas¹³, Aditya Mahadevan Iyer¹⁵, Theodoulos Rodosthenous¹⁶, Melissa Fernandes¹³, Thomas Calzascia¹³, Richard Siegel¹³, Peter Gergely¹³ and Tamas Shisha¹³, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ³APHP, Paris, France, ⁴Department of Nephrology and Rheumatology and Center of Immunotherapy, Medical Center of the Johannes Gutenberg University, Mainz, Germany, ⁵Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁶CNRS-UMR ⁵¹⁶⁴ Immuno ConcEpT, Bordeaux University and Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-³³⁰⁰⁰, Bordeaux, France, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁸Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁹Department of Rheumatology, Hopitaux Universitaires de Strasbourg, Centre National de Référence RESO, Strasbourg, France, ¹⁰Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹¹Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, ¹²Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹³Novartis Biomedical Research, Basel, Switzerland, ¹⁴Novartis Biomedical Research, Cambridge, MA, ¹⁵Novartis Biomedical Research, Hyderabad, India, ¹⁶Novartis Pharmaceuticals UK Ltd, London, United Kingdom
Background/Purpose: Current evidence suggests that B cell depletion through CD19-directed chimeric antigen receptor T cell (CAR-T) therapies may offer promise in improving outcomes in severe…
Abstract Number: 2602 • ACR Convergence 2025
Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Masahiro Nakano¹, Michihiro Kono¹, Kenichiro Asahara¹, Takayuki Katsuyama², Eri Katsuyama³, Takahiro Arakawa¹, Tsugumi Kawashima¹, Hajime Inokuchi¹, Takahiro Nishino¹, Haruka Takahashi¹, Bunki Natsumoto¹, Hiroaki Hatano¹, Yoshinori Matsumoto² and Kazuyoshi Ishigaki¹, ¹Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unknown etiology. While we previously identified key gene signatures of SLE using bulk RNA-seq…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 2450 • ACR Convergence 2025
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Irene Carrión-Barberà¹, Tarek Salman Montes², Laura Triginer³, Judit Font-Urgelles⁴, Anne Riveros frutos⁵, Sandra Garrote Corral⁶, Maria Garcia-Villanueva⁷, Carlos de Frías Polo⁸, María Galindo-Izquierdo⁹, Berta Magallares¹⁰, Andrea Hernández-martín¹¹, Jorge Juan Fragío Gil¹², Sebastián Sandoval Moreno¹³, Consuelo Ramos Giraldez¹⁴, Josefina Cortés-Hernández¹⁵, Elvira Díez García¹⁶, Clara Moriano¹⁷, Paloma Vela Casasempere¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Irene Altabás-González²⁰, Samuel Hernández-Baldizón²¹, Leyre Riancho²², Inmaculada Ros Vilamajo²¹, Carlos Marras Fernández-Cid²³, Maria Piqueras García²⁴, Angel Garcia-Aparicio²⁵, marta Garijo Bufort²⁶, José Gomez-Puerta²⁷, Beatriz Frade Sosa²⁸, Silvia García Cirera²⁹, Vicenç Torrente-Segarra³⁰, Luis Sala³¹, Concepción Fito-Manteca³², Natividad del Val del amo³³, Julia Martínez Barrio³⁴, Jose Rosas Gómez de Salazar³⁵, Sergi Heredia³⁶, ana Urruticoechea-Arana³⁷, Anahy Maria Brandy³⁸, Maria Esther Uriarte³⁹, José María Pego-Reigosa⁴⁰ and Iñigo Rúa-Figueroa⁴¹, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Ramón y Cajal, Madrid, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario ¹² de octubre, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Bareclona, ¹¹Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ¹²Hospital General Universitario, Valencia, Spain, ¹³Hospital Universitario Vall d’Hebron, Barcelona, Spain, ¹⁴Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁵Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁶Complejo Asistencial Universitario de León, León, Spain, ¹⁷Hospital León, LEON, Castilla y Leon, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain, ²¹Hospital Son Llàtzer, Palma de Mallorca, Spain, ²²Hospital de Sierrallana, Torrelavega, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Servicio Murciano de Salud, Murcia, Spain, ²⁵Hospital Universitario de Toledo, Toledo, Spain, ²⁶Rheumatology Department, Hospital de Sagunto, Spain, Valencia, Spain, ²⁷Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²⁸Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁹Consorci Coporació Sanitaria Parc Taulí, Sabadell, Spain, ³⁰Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ³¹Hospital Universitario de Torrejón, Madrid, Spain, ³²Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, ³³Complejo Universitario de Navarra, Navarra, Spain, ³⁴Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ³⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ³⁶Hospital Moisès Broggi, Barcelona, Spain, ³⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁸Hospital Germans Trias i Pujol, Badalona, Spain, ³⁹Hospital Universitario Donostia, San Sebastian, Spain, ⁴⁰Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain
Background/Purpose: Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The…
Abstract Number: 2433 • ACR Convergence 2025
The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: Timely SLE diagnosis and treatment are critical to preventing irreversible organ damage and preserving quality of life. However, conventional biomarkers often underperform in patients…
Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Alice Horisberger¹, Emily Oakes², Eilish Dillon³, Ifeoluwakiisi Adejoorin², Julia Caldropoli³, Kathryne Marks², Takanori Sasaki³, Farbod Moghaddam⁴, Paul Sciore⁵, Marvin J. Fritzler⁶, Deepak Rao², May Choi⁷ and Karen H. Costenbader⁸, ¹Lausanne University Hospital, University of Lausanne, Laussane, Switzerland, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴University of Calgary, Calgary, Canada, ⁵MitogenDx, Calgary, AB, Canada, ⁶MitognDx, Calgary, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…
Abstract Number: 2396 • ACR Convergence 2025
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Gerber Gomez¹, Yipeng Cheng², Kristiana Nita², Michael Hausmann³, Christian Fischer¹ and Yasemin Ataman-Önal³, ¹Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ²AliveDx, Edinburgh, United Kingdom, ³AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…
Abstract Number: 2380 • ACR Convergence 2025
Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
Amiah Griffin, Pat Phisitkul, Sarah Green, Ashley Suh, Bryan Han, Jiaming Li, Catherine Mao and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Individuals with Systemic lupus erythematosus (SLE) face diagnostic delays that can lead to increased disease activity and organ damage. Using a large electronic health…
Abstract Number: 2206 • ACR Convergence 2025
Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
Catherine Deffendall¹, Sarah Green², Ashley Suh², Bryan Han² and April Barnado², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies exist that examine pregnancy outcomes in adolescents with SLE. To our knowledge, there have been no studies comparing SLE adolescent pregnancies to…
Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Joshua Skydel¹, Anna Leland², Reshma Ramachandran³, Fotios Koumpouras³ and Joshua Wallach², ¹Yale-New Haven Hospital, New Haven, CT, ²Rollins School of Public Health, Atlanta, GA, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
Abstract Number: 1848 • ACR Convergence 2025
DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
Nanako NIshiyama¹, Atsushi Manno¹, Tomohiro Honda², Shigeko Uryu¹, Yuichiro Imamura², Ryutaro Fukui³, Yusuke Murakami⁴, Kensuke Miyake⁵ and Yoshiaki Tomimori⁶, ¹Daiichi Sankyo Co., Ltd., Tokyo, Tokyo, Japan, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan, ³Chiba University, Tokyo, Japan, ⁴Musashino University, Tokyo, Japan, ⁵Chiba University, Chiba, Japan, ⁶Daiichi Sankyo, Inc., Basking Ridge, NJ
Background/Purpose: Toll-like receptor (TLR) 7 is a pattern recognition receptor that recognizes nucleic acids and is implicated in the pathogenesis of systemic lupus erythematosus (SLE).…
Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Christian Wright¹, Miles Smith², Rufei Lu², Catriona Wagner³, Aleksandra Bylinska², Carla Guthridge², Nicholas Domingez², Susan Macwana², Wade DeJager⁴, Marci Beel⁵, Joan Merrill⁶, Eliza Chakravarty², Ellen Goldmuntz⁷, Study Team ALE⁰⁶ Clinical⁸, Judith James² and Joel Guthridge², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁷NIAID/ NIH, Washington, DC, ⁸Autoimmunity Center of Excellence, Oklahoma City, OK
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Khadija Mohib¹, Rameez Qasim², Zaiya Waseem³, Shaheer Ahmad⁴ and Ahmad Ali Hussain⁵, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³AtlantiCare Regional Medical Center, New Jersey, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Allama Iqbal Medical College Lahore, Lahore
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…
Abstract Number: 1639 • ACR Convergence 2025
Concordance of Self-Reported Physical Functioning and Physical Performance in SLE: A Cross-Cohort Analysis
Laura Plantinga¹, Mrinalini Dey², Jessica Fitzpatrick³, Maria Dall'Era⁴, Charmayne Dunlop-Thomas⁵, Courtney Hoge⁵, S. Sam Lim⁶, C. Barrett Bowling⁷, Jinoos Yazdany³ and Patti Katz⁸, ¹University of California, San Francisco, San Francisco, CA, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³UCSF, San Francisco, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵Emory University, Atlanta, GA, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸UCSF, San Rafael, CA
Background/Purpose: Assessment of self-reported physical functioning is common in SLE and essential for high-quality SLE care. However, because many factors may influence self-reported physical function…
Abstract Number: 1539 • ACR Convergence 2025
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Muhammad Usman Hashmi¹, Paramarajan Piranavan², Yasmeen Sufi³, Zaira Nasir⁴, Zainab Azhar⁵, Shamaem Tariq⁵, Hamas Ul Hudaibia⁵, IMRAN SAEED⁶, Aayet Zulfiqar⁵, Natasha Rasool² and Anum Faiz⁷, ¹Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, ²University of Kentucky, Louisville, KY, ³Karachi Medical & Dental College, Karachi, Karachi, Pakistan, ⁴Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, ⁵Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, ⁶Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, ⁷Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan
Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].